Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin/Metformin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor / Biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin/Metformin is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Inadequate control on metformin alone: adds DPP‑4 inhibition to improve glycaemic control. - Combination with other oral antidiabetics: provides complementary mechanisms to achieve target HbA1c.

Adverse reactions may occur with Linagliptin/Metformin therapy.

Common Side Effects: - Nausea - Diarrhoea - Abdominal discomfort - Headache - Upper respiratory tract infection - Mild hypoglycaemia (when combined with sulfonylureas or insulin)

Serious or Rare Side Effects: - Lactic acidosis (metformin‑related) - Acute pancreatitis - Severe allergic reactions (e.g., angio‑edema, Stevens‑Johnson syndrome) - Hepatic dysfunction - Significant renal impairment - Severe hypoglycaemia requiring assistance

Before initiating therapy, consider the following precautions. - Renal function assessment: evaluate eGFR to determine suitability. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Concomitant hypoglycaemic agents: monitor for additive glucose‑lowering effect. - Pregnancy and lactation: assess risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep in the original pack, protect from moisture.

Linagliptin/Metformin may interact with several medicines.

Major Interactions (Avoid): - Iodinated contrast media: suspend metformin to prevent lactic acidosis. - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Strong CYP3A4 inhibitors: may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal clearance of metformin. - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors/ARBs: monitor renal function and electrolytes.